BioSpace News Archive

Mallinckrodt plc today announced that five scientific abstracts on the clinical and health economic outcomes of treatment with TERLIVAZ.

IMJUDO® (tremelimumab) in Combination With IMFINZI® (durvalumab) Approved in the US for Patients With Unresectable Liver Cancer.

Biofrontera Inc. announces the appointment of Fred Leffler as Chief Financial Officer, effective immediately.

Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs, today announced the presentation of biomarker data from PRISM-EXT, a Phase 2 open-label trial of CP101 in recurrent C. difficile infection (CDI), at the American College of Gastroenterology (ACG) 2022 Annual Scientific Meeting.

PaxMedica, Inc. (Nasdaq: PXMD), a clinical-stage biopharmaceutical company focused on the development of anti-purinergic drug therapies (“APT”) for the treatment of disorders with intractable neurologic symptoms such as autism spectrum disorder (“ASD”), today announced the appointment of Dr. Stefan Schwabe MD, PhD as Chief Medical Officer.

Ardelyx, Inc. (Nasdaq: ARDX) today announced that post-hoc analyses from its Phase 3 T3MPO trials will be presented in two posters at the 2022 American College of Gastroenterology Annual Scientific Meeting (ACG 2022) taking place in Charlotte, North Carolina from October 21-26, 2022 and virtually.

KaliVir Immunotherapeutics, Inc., a biotech company developing cutting-edge, multi-mechanistic oncolytic viral immunotherapy programs, today announced that Dr. Stephen Thorne, Co-Founder and CSO, will present data on its product candidate VET3-TGI at the 14th International Oncolytic Virotherapy Conference (IOVC), taking place October 23-26, 2022, in Karuizawa, Nagano, Japan.

Daiichi Sankyo (TSE: 4568) received notification of acceptance by the U.S. Food and Drug Administration (FDA) of the New Drug Application (NDA) of quizartinib in combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy, and as continuation monotherapy following consolidation, for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3-ITD positive.

Ferring Pharmaceuticals today announced the presentation at the American College of Gastroenterology (ACG) 2022 Annual Scientific Meeting of seven analyses for RBX2660, an investigational microbiota-based live biotherapeutic studied for its potential to reduce recurrent C. difficile infection (CDI) after antibiotic treatment.

Establishment Labs Holdings Inc. (NASDAQ: ESTA) plans to announce its financial results for the quarter ended September 30, 2022 after the market closes on Monday, November 7, 2022, and will host a conference call at 4:30 pm ET that day to discuss those results.